1. Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin’s Lymphoma Study Group
by H. Tesch, V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Rüffer, A. Engert, J. Franklin, M. Pfreundschuh, K.P. Schalk, G. Schwieder, G. Wulf, G. Dölken, P. Worst, P. Koch, N. Schmitz, U. Bruntsch, C. Tirier, U. Müller, and M. Loeffler
Blood
Volume 92(12):
December 15, 1998
©1998 by American Society of Hematology

2. Evolution of dose levels in the BEACOPP scheme.
Evolution of dose levels in the BEACOPP scheme. Each dot represents the initial dose level of a patient recruited in the study. Dose escalation in the cohort of patients was performed as described.
H. Tesch et al. Blood 1998;92:
©1998 by American Society of Hematology

3. Comparison of the intended dose levels of cyclophosphamide and etoposide with the actual given levels achieved on average in all cycles.
Comparison of the intended dose levels of cyclophosphamide and etoposide with the actual given levels achieved on average in all cycles. Intended dose refers to the initial dose level in the first cycle for each patient and to the intended course duration of 8 × 21 days. Actual dose intensities refer to the total given dose and to the actual duration of the course of all given cycles (last cycle taken as 21 days). Patients separated according to sex and arranged in order of increasing initial dose level. (▴) Given DI of C; (•) given DI of E; (▴) intended DI of C; (•) intended DI of E.
H. Tesch et al. Blood 1998;92:
©1998 by American Society of Hematology

4. Occurence of toxic events in individual patients treated at different dose levels.
Occurence of toxic events in individual patients treated at different dose levels. (▪) Toxic response; (○) no toxicity.
H. Tesch et al. Blood 1998;92:
©1998 by American Society of Hematology

5. Estimates of FFTF and SV for patients treated with BEACOPP
Estimates of FFTF and SV for patients treated with BEACOPP. FFTF, freedom from treatment failure; SV, overall survival.
Estimates of FFTF and SV for patients treated with BEACOPP. FFTF, freedom from treatment failure; SV, overall survival. (□) FF; (◊) 7 failed/60; (□) SV; (+) 6 dead/60.
H. Tesch et al. Blood 1998;92:
©1998 by American Society of Hematology